Press Releases | Medtronic

Month Year

Email alerts

Apr 4, 2013

Medtronic Receives 'CE' Mark for Sentrant Introducer Sheath, Complementing Market-Leading Aortic Stent Grafts

Distinguishing Features of New Accessory for Endovascular Interventions Include Optimal Seal for Superior Hemostasis and Reinforced Coil for Proven Kink Resistance

MINNEAPOLIS -- April 4, 2013 -- Complementing its market-leading portfolio of stent grafts for the endovascular repair of aortic aneurysms and related conditions, Medtronic, Inc. (NYSE: MDT)...
Apr 2, 2013

Medtronic Announces FDA Clearance and First Uses of New Oxygenation System for Adult Cardiac Surgery

New System Designed for Patient Safety, Ease of Use During Open-Heart Procedures

MINNEAPOLIS - April 2, 2013 - Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the first U.S. clinical uses of its new Affinity Fusion®...
Mar 19, 2013

Medtronic Announces Public Offering of Senior Notes

MINNEAPOLIS -- March 19, 2013 -- Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $1.0 billion of its 1.375% Senior Notes due 2018, $1.25 billion of its 2.750% Senior Notes due...
Mar 11, 2013

With Medtronic Resolute Stent, Interrupting Dual Antiplatelet Therapy After One Month Showed No Increased Safety Risk in Robust Analysis

ACC.13 Presentation Features Unprecedented Data on Nearly 5,000 Patients, Including "All Comers," from Global RESOLUTE Clinical Program

SAN FRANCISCO -- March 11, 2013 -- Cardiologists at ACC.13 learned today that patients with coronary artery disease who received a Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) as...
Mar 10, 2013

New Data Reinforce Significant Blood Pressure Reduction Sustained to Two Years Using the Symplicity(TM) Renal Denervation System

24-Month Clinical Update from Symplicity HTN-2 Presented Today at the 62nd Annual Scientific Session of the American College of Cardiology

MINNEAPOLIS and SAN FRANCISCO - March 10, 2013 - Medtronic, Inc. (NYSE: MDT) today announced 24-month data from Symplicity HTN-2, the first randomized clinical trial investigating renal...
Mar 8, 2013

Medtronic CFO Gary Ellis to Speak at Barclays Global Healthcare Conference

MINNEAPOLIS - Mar 8, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Barclays Global Healthcare Conference on...
Mar 7, 2013

Medtronic Submits IDE to FDA for U.S. Randomized Clinical Trial for Uncontrolled Hypertension Patients with Systolic Blood Pressure Between 140-160 mm Hg

IDE Submission for Symplicity HTN-4 Expands the Indicated Patient Population and Builds upon Medtronic's Rigorous Global Clinical Trial Program for Hypertension Treatment

MINNEAPOLIS - March 7, 2013 - Medtronic, Inc. (NYSE: MDT), announced today that the company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA)...
Mar 6, 2013

Symplicity(TM) Renal Denervation System One of First Devices Accepted to Participate in Concurrent Review for Joint FDA Premarket Approval and Medicare National Coverage Determination

FDA-CMS Parallel Review Program Designed to Enable Efficient and Earlier Patient Access to Innovative Medical Advancements

MINNEAPOLIS - March 6, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA)and the Centers for Medicare & Medicaid Services (CMS) have accepted the...
Mar 5, 2013

Medtronic Announces CE Mark and European Launch of Attain Performa® Portfolio of Quadripolar Leads

New Lead Portfolio Provides Options for Physicians to Deliver CRT Optimally and Efficiently

MINNEAPOLIS - March 5, 2013 - Medtronic, Inc. (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark and will begin the European launch of the Attain Performa® portfolio of...
Mar 4, 2013

Medtronic Approved to Update Resolute Integrity Stent's 'CE' Mark Labeling on Dual Antiplatelet Therapy

Interruption or Discontinuation After One Month Following Implant Procedure Posed 'Low and No Increased Risk' of Stent Thrombosis at One Year in Clinical Studies

MINNEAPOLIS -- March 4, 2013 -- Of relevance to the clinical practice of interventional cardiology, Medtronic, Inc. (NYSE: MDT) announced today that it has received regulatory approval to update...

Show per page